Advertisement

Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects

      Abstract

      The purpose of this double-blind, randomized, placebo-controlled trial was to determine the long-term effects of pravastatin and fosinopril treatment on peripheral endothelial function in subjects with albuminuria. Subjects (mean age 51 years, 63% male) were randomized to pravastatin 40 mg or matching placebo and to fosinopril 20 mg or matching placebo. Using high resolution ultrasound, flow-mediated dilation (FMD) and nitroglycerin-induced dilation (NID) was assessed at baseline and after 4 years of treatment in a total of 276 subjects. At baseline, mean ± standard error FMD was 4.73 ± 0.49% and NID was 10.86 ± 0.67%. Pravastatin significantly reduced total cholesterol and LDL cholesterol (p < 0.01) and randomization to pravastatin was associated with a non-significant improvement of 18.9% in FMD (+0.80 ± 0.95, p = 0.09), without a significant change in NID. Interestingly, pravastatin significantly increased FMD by 34.9% in men (+1.23, p = 0.04), but only 1.1% in women (+0.06, p = 0.95). Fosinopril was not associated with a change in FMD or NID despite significantly decreasing urinary albumin excretion, systolic and diastolic blood pressure (all p < 0.01). In conclusion, after 4 years of follow-up, pravastatin treatment tended to increase FMD and this effect was predominantly present in men. Fosinopril treatment did not modify FMD during long-term follow-up.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ross R.
        Atherosclerosis—an inflammatory disease.
        N Engl J Med. 1999; 340: 115-126
        • Vita J.A.
        • Treasure C.B.
        • Nabel E.G.
        • et al.
        Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.
        Circulation. 1990; 81: 491-497
        • Furchgott R.F.
        • Zawadzki J.V.
        The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
        Nature. 1980; 288: 373-376
        • Asselbergs F.W.
        • van der H.P.
        • Jessurun G.A.
        • Tio R.A.
        • van Gilst W.H.
        Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins.
        Vascul Pharmacol. 2005; 42: 125-140
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • et al.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Yusuf S.
        • Sleight P.
        • Pogue J.
        • Bosch J.
        • Davies R.
        • Dagenais G.
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators.
        N Engl J Med. 2000; 342: 145-153
        • Fox K.M.
        Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
        Lancet. 2003; 362: 782-788
        • Hillege H.L.
        • Fidler V.
        • Diercks G.F.
        • et al.
        Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.
        Circulation. 2002; 106: 1777-1782
        • Asselbergs F.W.
        • Diercks G.F.
        • Hillege H.L.
        • et al.
        Effects of Fosinopril and Pravastatin on cardiovascular events in microalbuminuric subjects.
        Circulation. 2004; 110: 2809-2816
        • Diercks G.F.
        • Stroes E.S.
        • Boven A.J.
        • et al.
        Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects.
        Atherosclerosis. 2002; 163: 121-126
        • Hijmering M.L.
        • Stroes E.S.
        • Pasterkamp G.
        • Sierevogel M.
        • Banga J.D.
        • Rabelink T.J.
        Variability of flow mediated dilation: consequences for clinical application.
        Atherosclerosis. 2001; 157: 369-373
        • Dupuis J.
        • Tardif J.C.
        • Cernacek P.
        • Theroux P.
        Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial.
        Circulation. 1999; 99: 3227-3233
        • Ohara Y.
        • Peterson T.E.
        • Harrison D.G.
        Hypercholesterolemia increases endothelial superoxide anion production.
        J Clin Invest. 1993; 91: 2546-2551
        • Tamai O.
        • Matsuoka H.
        • Itabe H.
        • Wada Y.
        • Kohno K.
        • Imaizumi T.
        Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.
        Circulation. 1997; 95: 76-82
        • Fichtlscherer S.
        • Rosenberger G.
        • Walter D.H.
        • Breuer S.
        • Dimmeler S.
        • Zeiher A.M.
        Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease.
        Circulation. 2000; 102: 1000-1006
        • Ridker P.M.
        • Rifai N.
        • Pfeffer M.A.
        • Sacks F.
        • Braunwald E.
        Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators.
        Circulation. 1999; 100: 230-235
        • Ling M.C.
        • Ruddy T.D.
        • deKemp R.A.
        • et al.
        Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease.
        Am Heart J. 2005; 149: 1137
        • Stein J.H.
        • Merwood M.A.
        • Bellehumeur J.L.
        • et al.
        Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors.
        Am Heart J. 2004; 147: E18
        • Karatzis E.
        • Lekakis J.
        • Papamichael C.
        • et al.
        Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina.
        Int J Cardiol. 2005; 101: 65-70
        • Kayikcioglu M.
        • Payzin S.
        • Yavuzgil O.
        • Kultursay H.
        • Can L.H.
        • Soydan I.
        Benefits of statin treatment in cardiac syndrome-X1.
        Eur Heart J. 2003; 24: 1999-2005
        • Hornig B.
        • Arakawa N.
        • Haussmann D.
        • Drexler H.
        Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure.
        Circulation. 1998; 98: 2842-2848
        • Wilmink H.W.
        • Banga J.D.
        • Hijmering M.
        • Erkelens W.D.
        • Stroes E.S.
        • Rabelink T.J.
        Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function.
        J Am Coll Cardiol. 1999; 34: 140-145
        • McFarlane R.
        • McCredie R.J.
        • Bonney M.A.
        • et al.
        Angiotensin converting enzyme inhibition and arterial endothelial function in adults with type 1 diabetes mellitus.
        Diabet Med. 1999; 16: 62-66
        • Anderson T.J.
        • Elstein E.
        • Haber H.
        • Charbonneau F.
        Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study).
        J Am Coll Cardiol. 2000; 35: 60-66
        • Kathiresan S.
        • Gona P.
        • Larson M.G.
        • et al.
        Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function.
        Circulation. 2006; 113: 938-945
        • Levenson J.
        • Pessana F.
        • Gariepy J.
        • Armentano R.
        • Simon A.
        Gender differences in wall shear-mediated brachial artery vasoconstriction and vasodilation.
        J Am Coll Cardiol. 2001; 38: 1668-1674
        • Kuvin J.T.
        • Patel A.R.
        • Sidhu M.
        • et al.
        Relation between high-density lipoprotein cholesterol and peripheral vasomotor function.
        Am J Cardiol. 2003; 92: 275-279
        • Spieker L.E.
        • Sudano I.
        • Hurlimann D.
        • et al.
        High-density lipoprotein restores endothelial function in hypercholesterolemic men.
        Circulation. 2002; 105: 1399-1402